Extended-spectrum β-lactamases: Will they be the new 'methicillin-resistant Staphylococcus aureus'?

BJU International

Volumn 101, Issue 2, 2008, Pages 151-152

  Hicks, James A ^a   Harris, Mark R E ^b   Keoghane, Stephen R ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b SALISBURY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFACLOR; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; PENICILLIN G; QUINOLONE DERIVATIVE; TRIMETHOPRIM;

BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM DETECTION; ENZYME ACTIVITY; ESCHERICHIA COLI; EUROPE; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; LABORATORY TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; NONHUMAN; NORTH AMERICA; NOTE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SOUTH AMERICA; STENOTROPHOMONAS MALTOPHILIA; UNITED KINGDOM; URINALYSIS;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; ESCHERICHIA COLI INFECTIONS; FOSFOMYCIN; HUMANS; KLEBSIELLA INFECTIONS; NITROFURANTOIN;

EID: 37349018635     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07200.x     Document Type: Note

References (10)

1. Potz NA, Hope R, Warner M, Johnson AP, Livermore DM London & South East ESBL Project Group. Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England. J Antimicrob Chemother 2006 58 : 320 6
2. Gniadkowski M. Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001 7 : 597 608
3. Sader HS, Hsiung A, Fritsche TR, Jones RN. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis 2007 57 : 341 4
4. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001 32 (Suppl. 2 S94 103
5. De Champs C, Sirot D, Chanal C, Bonnet R, Sirot J and the French Study Group. A 1998 survey of extended-spectrum beta-lactamases in Enterobacteriaceae in France. The French Study Group. Antimicrob Agents Chemother 2000 44 : 3177 9
6. Steward CD, Wallace D, Hubert SK et al. Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories. Diagn Microbiol Infect Dis 2000 38 : 59 67
7. Ena J, Arjona F, Martinez-Peinado C, Lopez-Perezagua M, Amardor C. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology 2006 68 : 1169 74
8. Thouverez M, Talon D, Bertrand X. Control of Enterobacteriaceae producing extended-spectrum beta-lactamase in intensive care units: rectal screening may not be needed in non-epidemic situations. Infect Control Hosp Epidemiol 2004 25 : 838 41
9. Lee SY, Kotapti S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 2006 27 : 1226 32
10. Conterno LO, Shymanski J, Ramotar K, Toye B, Zvonar R, Roth V. Impact and cost of infection control measures to reduce nosocomial transmission of extended-spectrum beta-lactamase-producing organisms in a non-outbreak setting. J Hosp Infect 2007 65 : 354 60